Study offers new insights into why some CAR T-cells persist in children with leukemia

New insights explaining why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukemia have been revealed by researchers at UCL, Great Ormond Street Hospital, and the Wellcome Sanger Institute.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Sam Behjati ,Henry Stennett ,Sara Ghorashian ,Nathaniel Anderson ,Danielle Ellis ,Wellcome ,University College London Hospital ,Institute Of Child Health ,Jp Moulton ,King Health Partners ,Research Information ,Olivia Hodson Cancer Fund ,Wellcome Senior Research ,Children Charity ,Care Research Biomedical Centres ,Wellcome Sanger Institute ,Cancer Research United Kingdom ,National Institute For Health ,Great Ormond Street Hospital ,Wellcome Sanger ,Nature Medicine ,Ormond Street Institute ,Child Health ,Marie Sklodowska Curie Fellow ,Paediatric Haematology ,Honorary Senior Clinical Lecturer ,Group Lead ,Wellcome Senior Research Fellow ,Honorary Consultant Paediatric Oncologist ,Research Information Manager ,Award Scheme ,Sklodowska Curie Actions ,National Institute ,Health Partners ,University College London ,